Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.42 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.42 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28095334 | 0.86 | ARG1 (0.52) | HPGDARG1ARG2CETP | |
| SCHEMBL9336511 | 0.84 | ARG1 (0.51) | HPGDTNNC1S1PR1S1PR4S1PR3 | |
| SCHEMBL28431794 | 0.83 | TNNC1 (0.43) | HPGDTNNC1S1PR1S1PR4S1PR3 | |
| SCHEMBL14478224 | 0.78 | ARG1 (0.66) | ARG1ARG2 | |
| SCHEMBL28747146 | 0.78 | GRM2 (0.43) | HDAC3LMNAARG1ARG2GRM2 | |
| SCHEMBL10672100 | 0.77 | ALDH1A1 (0.52) | HDAC3LMNAARG1ARG2GRM2 | |
| SCHEMBL9016870 | 0.76 | TNNC1 (0.53) | TNNC1S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL19438904 | 0.76 | GRM2 (0.50) | HPGDHDAC3LMNAARG1ARG2 | |
| Butylbenzyl SCHEMBL28302597 | 0.76 | ALDH1A1 (0.60) | HPGDHDAC3LMNA | |
| SCHEMBL3806647 | 0.75 | FDPS (0.43) | LMNAARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553809-B2 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2009-06-30 | — | — | US | disclosed |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | ILEXUS PTY LIMITED (AU) | 2006-03-16 | — | — | US | disclosed |
| US-6835753-B2 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED (AU) | 2004-12-28 | — | — | US | disclosed |
| EP-1109545-A4 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2004-11-10 | — | — | EP | disclosed |
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | ILEXUS PTY LIMITED | 2002-05-23 | — | — | US | disclosed |
| US-6355683-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | ILEXUS PTY LIMITED (AU) | 2002-03-12 | — | — | US | disclosed |
| EP-1109545-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LTD (AU) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000015214-A1 | Fc RECEPTOR MODULATORS AND USES THEREOF | ILEXUS PTY LIMITED (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061844-A1 | Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt | FCGR2A, FCGR1A, FCER2 | HPGD 2962/4885HDAC3 3520/4885TNNC1 3032/4885 |
| US-20060057144-A1 | Fc receptor modulators and uses thereof | FCGR1A, FCER2, FCGR2A | HPGD 1881/4885HDAC3 3251/4885TNNC1 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.